P-31 changes as a measure of therapy response in resistant and sensitive osteosarcomas implanted into nude mice.
暂无分享,去创建一个
B. Croker | J R Ballinger | H Kang | C A Sweeney | J D Scott | B P Croker | K N Scott | K. Scott | C. Sweeney | J. Ballinger | H. Kang | J. Scott
[1] B. Croker,et al. Mesenchymal specificity of three new monoclonal antibodies generated to the osteosarcoma cell line 4444T. , 1991, Clinical immunology and immunopathology.
[2] J. Denekamp. The choice of experimental models in cancer research: The key to ultimate success or failure? , 1992, NMR in biomedicine.
[3] W. Aue,et al. Extremity bone tumors: evaluation by P-31 MR spectroscopy. , 1985, Radiology.
[4] R. Lenkinski,et al. Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy of Bone Tumors and Bone Marrow Disease , 1989, Investigative radiology.
[5] V. Courtenay,et al. The response to chemotherapy of a variety of human tumour xenografts. , 1983, British Journal of Cancer.
[6] P. Chang. Bayesian analysis revisited: a radiologist's survival guide. , 1989, AJR. American journal of roentgenology.
[7] K. Wolf,et al. 31P nuclear magnetic resonance spectroscopy, histology and cytokinetics of a xenografted hypopharynx carcinoma following treatment with cisplatin: comparison in three sublines with increasing resistance. , 1991, British Journal of Cancer.
[8] J. Rygaard,et al. Immune-deficient animals in biomedical research , 1987 .
[9] T. Ng,et al. Faraday shield for surface-coil studies of subcutaneous tumors , 1982 .
[10] W. J. Lorenz,et al. Monitoring human tumor response to therapy by means of P-31 MR spectroscopy. , 1988, Radiology.
[11] P. Köpf-Maier,et al. 31P NMR spectroscopy of a xenografted hypopharynx carcinoma: Effects of tumor growth and treatment with cisplatin on the tumor phosphorus metabolism, histology and cytokinetics , 1992, NMR in biomedicine.
[12] D. Dorfman,et al. Maximum-likelihood estimation of parameters of signal-detection theory and determination of confidence intervals—Rating-method data , 1969 .
[13] M. Inaba,et al. Pharmacokinetic Approach to Rational Therapeutic Doses for Human Tumor‐bearing Nude Mice , 1988, Japanese journal of cancer research : Gann.
[14] J. Zheng,et al. Immune-deficient animals in experimental medicine. , 1989 .
[15] C E Metz,et al. Some practical issues of experimental design and data analysis in radiological ROC studies. , 1989, Investigative radiology.
[16] M. Clerici,et al. Growth kinetics and in vivo radiosensitivity in nude mice of two subpopulations derived from a single human small cell carcinoma of the lung. , 1986, European journal of cancer & clinical oncology.
[17] W. Negendank,et al. Studies of human tumors by MRS: A review , 1992, NMR in biomedicine.
[18] B. Croker,et al. 31P changes as a measure of therapy response in human osteosarcomas implanted into nude mice. , 1994, Magnetic resonance imaging.
[19] J. Stack,et al. Osteosarcoma: use of MR imaging and MR spectroscopy in clinical decision making. , 1989, Radiology.
[20] I. Young,et al. Osteosarcoma and other neoplasms of bone. Magnetic resonance spectroscopy to monitor therapy. , 1987, Archives of surgery.
[21] J. Hanley,et al. The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.
[22] R. R. Ernst,et al. Application of Fourier Transform Spectroscopy to Magnetic Resonance , 1966 .
[23] J. Evelhoch,et al. Response-specific adriamycin sensitivity markers provided by in vivo 31P nuclear magnetic resonance spectroscopy in murine mammary adenocarcinomas. , 1987, Cancer research.
[24] G. Rosen,et al. Adjuvant chemotherapy of osteosarcoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] C. Metz. Basic principles of ROC analysis. , 1978, Seminars in nuclear medicine.